Todd Zavodnick, Dermavant CEO
Dermavant's Vtama works again in eczema as Roivant subsidiary seeks label expansion next year
Almost a year to the day after Dermavant Sciences landed its first FDA approval for plaque psoriasis for Vtama, the drugmaker is out with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
